Package Insert: Information for the Patient
Mulpleo 3 mg Film-Coated Tablets
lusutrombopag
Read the entire package insert carefully before starting to take this medication, as it contains important information for you.
Mulpleo contains the active ingredient lusutrombopag, which belongs to a group of medications called thrombopoietin receptor agonists. The medication helps to increase the number ofplateletsin the blood. Platelets are blood components that help to coagulate the blood and thus prevent bleeding.
Mulpleo is used toreduce the risk of bleeding during surgical and other procedures(including dental extractions and endoscopy). It is administered to adults with low platelet counts due to chronic liver disease.
Do not take Mulpleo:
?Consult your doctorbefore starting to take Mulpleo, if this is your case.
Warnings and precautions
Consult your doctor:
?Consult your doctorbefore taking Mulpleo, if this is your case.
Blood clot signs:be aware of the following signs:
?Seek medical attention immediatelyif you notice any of these signs.
Children and adolescents
Do not give this medicine to children oradolescents under 18 years of age, as the medicine has not been studied in children and adolescents.
Other medicines and Mulpleo
Inform your doctor if you are taking, have taken recently or may need to take any other medicine.
Pregnancy and breastfeeding
Do not take Mulpleounless your doctor recommends it specifically. The effect of Mulpleo during pregnancy is unknown.
Do not breastfeed during treatmentwith Mulpleo, as it is unknown if the medicine passes into breast milk.
→If you are already breastfeeding, speak with your doctor immediately.
Driving and operating machines
Mulpleo has no known effect on the ability to drive or operate machines.
Mulpleo contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Recommended dose:Take one tablet once a day, at the same time every day, for only seven days. Take the tablet with a liquid and swallow it whole. Do not chew, break, or crush the tablet. You can take it with food or between meals.
Your treatment will begin at least 8 days before your surgical operation or procedure. Do not change the dose or dosing schedule of Mulpleo unless instructed by your doctor or pharmacist.
If you have severe liver disease,inform your doctor before taking Mulpleo.
If you take more Mulpleo than you should
If you have taken more Mulpleo than you should, talk to your doctor or go to the hospital. If possible, show the packaging or this leaflet. You may be monitored for adverse effects associated with excessive platelets, such as blood clots (see section 2 «Warnings and precautions», and section 4 «Possible side effects»).
If you forgot to take a tablet
If you forgot to take a Mulpleo tablet, take it as soon as possible on the same day.
Do not take a double dose to make up for the missed dose.
If you interrupt treatment with Mulpleo
Do not stop taking Mulpleo without talking to your doctor and do not take Mulpleo for more than 7 days.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
Increased risk of blood clots
Certain people may be at a higher risk of developing blood clots — including people with liver disease — and medications like Mulpleo may exacerbate this problem.
Symptoms of a blood clot: Be aware of the following symptoms:
? Seek medical attention immediately if you notice any of these symptoms.
Adverse effects that occur frequently
(may affect up to 1 in 10 people)
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the national notification system included in the Appendix V .
By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the blisters after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture.
This medication does not require any special storage temperature.
Medications should not be disposed of through drains or trash. Ask your pharmacist how to dispose of the containers and medications you no longer need. This will help protect the environment.
Appearance of the product and contents of the package
Mulpleo 3 mg film-coated tablets are film-coated tablets of 7.0 mm in diameter, round, and light red in color, engraved with the commercial brand name of Shionogi above the identifier code “551” on one side and the concentration “3” on the other.
Mulpleo is presented in aluminum blisters in a box containing 7 film-coated tablets.
Marketing Authorization Holder
Shionogi B.V.
Herengracht 464
1017CA Amsterdam
Netherlands
Responsible for manufacturing
Shionogi B.V.
Herengracht 464
1017CA Amsterdam
Netherlands
For more information about this medicine, please contact the local representative of the marketing authorization holder:
AT, BE, BG, CY, CZ, DK, EE, IE, EL, FI, HR, HU, IE, IS, LT, LU, LV, MT, NL, NO, PL, PT, RO, SE, SI, SK Shionogi B.V. Tel/Tel./Teπ./Tlf/Tél/Puh/Sími/Τηλ: +31204917439 contact@shionogi.eu | DE Shionogi GmbH Tel: +49 (0) 30 2062980 66 kontakt@shionogi.eu |
ES Shionogi SLU Tel: +34 911 239 258 contacta@shionogi.eu | IT Shionogi Srl Tel: +39 06 94 805 118 contattaci@shionogi.eu |
FR Shionogi SAS Tel: +33 (0)1 86 65 58 06 contactfrance@shionogi.eu | UK (NI) Shionogi B.V. Tel: +44 (0) 28 9124 8945 contact@shionogi.eu |
Last review date of this leaflet: January 2024
Other sources of information
Further information on this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.eu/.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.